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ABSTRACT OF THE THESIS 
DEVELOPMENT OF A MALDI-TOF-MS METHOD FOR THE ANALYSIS OF 
CYANOBACTERIAL NEUROTOXIN β-N-METHYLAMINO-L-ALANINE (BMAA) 
IN SEARCH OF BMAA INCORPORATION IN BIOLOGICAL SAMPLES 
by 
Laura M. Conklin 
Florida International University, 2015 
Miami, Florida 
Professor John Berry, Major Professor 
Beta-N-methylamino-L-alanine (BMAA) is a non-protein amino acid produced by 
many cyanobacteria, and thought to induce neurotoxic effects through excitotoxicity, 
contributing to neurodegenerative diseases such as Amyotrophic Lateral 
Sclerosis/Parkinsonism-dementia complex (ALS-PDC) and Alzheimer’s.  The ubiquitous 
nature of cyanobacteria, and evidence of biomagnification through our food web, creates 
a dire need for the development of an analytical platform that will provide accurate 
identification and quantification of BMAA amounts in our ecosystem and potential food 
supply.  The present study evaluated the ability of a MALDI-ToF-MS method to detect 
and quantify BMAA in a variety of biological matrices.  Through validation procedures, 
it was demonstrated that this MALDI-ToF-MS method provided comparable data to 
currently accepted analytical methods, specifically LC-MS/MS.  Further, the 
development of said method reduced sample preparation and data acquisition time (1-2 
seconds per sample), while providing high throughput analysis and eliminating the need 
for derivatization, chromatographic separation, and modification of amino acids.  
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1. INTRODUCTION AND LITERATURE REVIEW 
The connection between β-N-methylamino-L-alanine (BMAA) and Amyotrophic 
Lateral Sclerosis/Parkinsonism-dementia complex (ALS-PDC) came to light in 1953 
when a medical report was released stating that on the island of Guam, the incidence rate 
of ALS-PDC among the native Chamorro people was 100-fold higher than anywhere else 
in the world (Arnold et al., 1953).  In this report, however, it was thought that genetic 
variations among the Chamorro people was the causative factor for the increased 
incidence of ALS-PDC (Arnold et al., 1953).  Once researchers failed to correlate a 
genetic causation to the increased incidence of ALS-PDC, they turned to possibility of 
environmental factors being the cause (Spencer et al., 1986).  The Chamorro people 
consume a diet that relies heavily the seeds of the native Cycad tree to produce flour 
(Murch et al., 2004).  It was then suggested that the consumption of these seeds from the 
Cycad tree was the cause of the increased rate of this specific neurodegeneration among 
the Chamorro people, deeming this hypothesis as, “The Cycad Hypothesis” (Murch et al., 
2004).   
It was not until 1967 in a study conducted by Vega et al, that BMAA was isolated 
from the seeds of the cycad tree and found to have neurotoxic effects after being injected 
into chicks and rats, causing symptoms that paralleled that of patients suffering from 
neurodegenerative diseases such as ALS-PDC and Alzheimer’s (Vega et al., 1967).    
Various studies done on rats, chicks, macaques, and mice, further supported a new 
hypothesis that BMAA was the component of the cycad seeds that was the causative 
agent of neurodegeneration.  At this point in time, the origin of BMAA was still 
unknown.  In 2003, it was found that BMAA was a non-protein amino acid that was 
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being produced by the cyanobacterial genus Nostoc as a symbiont to the coralloidal roots 
of the cycad tree (Murch et al., 2004).  Figure 1 depicts the chemical structure of BMAA.  
In this study, by Murch, et al. (2004), not only was BMAA identified as a product of this 
cyanobacteria, but evidence of biomagnification through the cycad tree and further into 
the food web to the Chamorro people was seen.  By analyzing various portions of the 
cycad tree (i.e., roots, leaves, and seeds) and the hair and skin of a species of Flying Fox, 
a type of fruit bat, that forages on the seeds, levels of BMAA were seen to have increased 
along the food web, accumulating along the way, until finally being consumed by the 
Chamorro people either through flour produced from the seeds of the cycad, or by the 
Flying Foxes who forage on the fruit and seeds of the Cycad tree (Murch et al., 2004).  
Further, this study found the presence of BMAA in brain tissues of patients who had 
suffered not only from ALS-PDS, but Alzheimer’s as well (Murch et al., 2004).  These 
findings provided evidence for the theory of the biomagnification of BMAA among food 
webs and also pushed for further research as to the role of BMAA in neurodegenerative 
diseases (Murch et al., 2004).  Other subsequent studies found that 90% of cyanobacterial 
species produced BMAA, suggesting that human exposure to this neurotoxin might be 
much more prevalent than previously thought (Cox et al., 2005).  Recent studies showing 
BMAA present in tissues of some of the top predators such as mussels and shark fins, 
suggest that the ability of this amino acid to biomagnify, could prove to be a serious risk 
to the entire human population, if the mode of action of the neurotoxin is the cause of 
many neurodegenerative diseases (Mondo et al., 2012).   
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Figure 1.  Chemical structure of the non-protein amino acid BMAA, produced by over 
90% of cyanobacteria. 
 
Currently, there is very little consensus as to a method of detection as well as an 
accurate technique for the analysis of BMAA.  The only true consensus regarding BMAA 
are the neurotoxic effects that it has on a cellular level based on in vivo studies, however, 
the link between BMAA and ALS has yet to be effectively demonstrated in an animal 
model (Karamyan et al., 2008; Duncan et al., 1991).  The ubiquitous nature of 
cyanobacteria and evidence of biomagnification through our food web, creates a need for 
researchers to clearly understand the mode of action by which BMAA exerts itself on 
primary motor neurons, and the development of an analytical platform that will provide 
accurate identification and quantification of BMAA amounts in our ecosystem and 
potential food supply.  The present project entails the development of an analytical 
method using MALDI-ToF/ToF-MS/MS that ensures the accurate identification and 
quantification of BMAA with minimal sample preparation.  By method development, 
clear reporting, validation and inter-laboratory comparisons, the discrepancies that 
currently exist regarding previous studies are diminished.  The development of such 
analytical platform aims to give researchers a better understanding of the extent or 
magnitude of human exposure to BMAA.   
4 
 
The aim of the current research is to provide an evaluation of MALDI-ToF/ToF-
MS/MS as an analytical platform for the identification and quantification of BMAA in a 
variety of matrices.  The research involves method development, validation studies, and 
subsequent employment to evaluate relevant biological samples from South Florida 
waters, where BMAA accumulation has been previously reported.  The MALDI-TOF 
technique was found to effectively measure BMAA in a range of biological matrices, and 
moreover, was notably able to discriminate, specifically by means of so-called MALDI-
TOF/TOF, BMAA from diaminobutyric acid (DAB), a structural isomer also produced 
by cyanobacteria, which has been suggested to potentially confound analytical results. 
The details of the techniques, including analytical results obtained from application to 
biological samples from South Florida waters, comparison to conventional (e.g. liquid 
chromatography/mass spectrometry) techniques and potential for understanding toxicity 
of BMAA will be discussed.   
The goal of developing a MALDI-TOF/TOF-MS/MS method is to offer another 
analytical platform that allows for minimal sample preparation, rapid analysis, while 
eliminating the need for derivatization, chromatographic separation and modification of 
amino acids.  If the proposed method were to be coupled to MALDI imaging mass 
spectrometry (IMS), accurate quantitation of BMAA along with visual spatial 
localization would be possible.    
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1.1. SUGGESTED MECHANISM OF BMAA – INDUCED 
NEURODEGENERATIVE EFFECTS  
 
On the basis of the current literature, there are many differences in opinion as to what 
the mode of activity BMAA puts forth on neuronal cells, however, many studies have 
shown significant evidence that BMAA has the capability of crossing the blood-brain 
barrier, competitively binding to glutamate receptors, causing chemical and cellular ion 
shifts that lead to depolarization, excitotoxicity, and eventually neuronal cell apoptosis 
(Duncan et al., 1991; Lobner et al., 2007; Cucchiaroni et al., 2010)  In 1991, Duncan, et 
al. (1991) studied the pharmacokinetics and the permeability of the blood-brain barrier, 
and were able to show that in a rat model, BMAA can cross the blood-brain barrier by an 
L-type amino acid carrier.  Lobner, et al. (2007) conducted a study in 2007 in which they 
looked that the synergistic effects of low doses of BMAA with amyloid-β and MPP+, 
both known neurotoxins.  Their study provided data suggesting that BMAA acts on 
NMDA receptors and another particular glutamate receptor (mGluR5) (Lobner et al., 
2007).  One other notable study was done by Cucchiaroni, et al. (2010) in which they 
found that an injection of BMAA caused an increase in Ca+, increased production of 
reactive oxygen species (ROS), and the heavy release of cytochrome-c into the cytosol in 
a rat neuron model.  The release of cytochrome-c could account for diminished 
mitochondrial activity, excitotoxicity, and cellular apoptosis.  In conclusion, after BMAA 
is consumed or ingested, it passes through the blood-brain barrier via L-type amino acid 
carriers, and then competitively binds to NMDA receptors along with other glutamate 
receptors (Cucchiaroni et al., 2010).  The binding of BMAA to NMDA and other 
glutamate receptors then causes cellular ion shifts of Ca+, Na+, and K+, an increase in 
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ROS production, depolarization of the cell, and a heavy release of cytochrome-c 
(Cucchiaroni et al., 2010).  This so called “excitotoxicity” mechanism could be the 
causative mode of activity of BMAA on neuronal cells, leading to many 
neurodegenerative diseases.   
More recently, and perhaps more notable, in a study done by Dunlop, et al. (2013), 
researchers incubated multiple types of human cells with 3H-BMAA and unlabeled 
BMAA and were able to determine that not only does BMAA become misincorporated 
into human proteins, but binding of BMAA is inhibited by L-serine.  Further, the study 
showed that the formation of autofluorescent bodies, that are characteristic of protein 
aggregation, was diminished by the co-incubation of BMAA and L-serine with human 
cells (Dunlop et al., 2013).  The diminished presence of autofluorescent bodies with the 
co-incubation of BMAA and L-serine, suggests that the misincorporation of BMAA into 
human cells is a protein-synthesis dependent process (Dunlop et al., 2013).  Figure 2 
shows the possible mechanism of BMAA misincorporation via a protein-synthesis 
dependent process (Dunlop et al., 2013).  It must be noted that the mechanism by which 
BMAA becomes incorporated into proteins and crosses the blood-brain barrier is still 
debated, however L-type amino acid transport has been suggested, and the studies 
described above are progressive steps to understanding the true mechanism by which 
BMAA acts.   
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Figure 2. Possible mechanism of BMAA misincorporation into proteins, as discussed by 
Dunlop, et al. in 2013 (Dunlop et al., 2013). 
 
1.2. COMMON METHODS OF ANALYSIS FOR BMAA 
Current methodology for the analysis of BMAA in a variety of biological matrices 
and mixtures of amino acids prepared by splitting proteins by means of acid hydrolysis, 
commonly referred to as protein hydrolysates, primarily include, high performance liquid 
chromatography with postcolumn fluorescence detection (HPLC-FLD), liquid 
chromatography mass spectrometry (LC-MS), and liquid chromatography tandem mass 
spectrometry (LC-MS/MS) using both derivatized and underivatized BMAA samples 
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(Faassen et al., 2012; Karlsson et al., 2012; Faasen et al., 2013).  The reported 
incorporation of BMAA into proteins, in protein hydrolysates, led to the universal use of 
hydrolysis procedures to account for all BMAA in a sample (bound and free).  All of 
these methods employ liquid chromatography, separating a mixture using a liquid mobile 
phase that carries the mixture through a stationary phase within a chromatographic 
column and further into a detector or mass spectrometer.  Researchers over the past 
decade have utilized a variety of methods and protocols regarding which analytical 
method produces data to best quantify BMAA in biological samples, and therefore, the 
published data has suggested to potentially overestimate and/or fail to detect BMAA in a 
sample.  Table 2 depicts the variety of analytical techniques that some research groups 
have used; the majority of research groups have chosen LC-MS/MS (Table 2).   
Table 1 describes the reported concentrations of BMAA in various matrices.  Over 
the last fifteen years, researchers have analyzed multiple samples that vary from cycad 
seeds to very complex matrices such as lobsters and brain tissues.  The amount of BMAA 
found in these matrices, varies from 0μg/g to 2,286μg/g (Table 1) (Banack et al., 2014; 
Brand et al., 2010; Christensen et al., 2012; Faasen et al., 2009; Karlsson et al., 2014; 
Mondo et al., 2014; Spacil et al., 2010).  
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Table 1. Concentrations of BMAA in different matrices from current literature. 
CITATION METHOD BMAA (μg/g) SAMPLE TYPE 
Fassen 2009 LC-MS/MS 4-42 Cyanobacterial 
blooms in Dutch 
urban waters 
Brand 2010 LC-MS/MS 275-2,286 Blue Crab, oyster, 
Puffer Fish, shrimp, 
White Perch 
Spacil 2010 HPLC-MS/MS 0-109.4 Prokaryotic 
cyanobacterium to 
Eukaryotic fish 
Christensen 2012 LC-MS/MS 19.1-50.1 Cycad, oyster, Blue 
Crab 
Mondo 2014 HPLC-FD 
 
HPLC-MS/MS 
86-265 
 
75-352 
Shark cartilage 
dietary supplements 
Karlsson 2014 HPLC-MS/MS 0.023-245.978 Liver and brain 
samples of rats 
Banack 2014 LC-MS/MS 0.4-27 Lobsters from 
Florida 
 
In most of the first studies in the early 2000’s, researchers began using 6-
aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC) derivatization prior to HPLC-
FLD (Banack et al., 2003; Cox et al., 2003; Murch et al., 2004).  Derivatizing agent, 
AQC adds a fluorescent “tag” to BMAA, making it detectable HPLC-FLD methods 
(Banack et al., 2003; Cox et al., 2003; Murch et al., 2004; Faassen et al., 2012; Mondo et 
al., 2012; Mondo et al., 2014).  Similarly, Esterhuizen-Londt (2011) used another 
derivatization method using propyl chloroformate, EZ-faast™.  The HPLC-FLD method 
has its drawbacks, which are discussed below.  Murch et al. (2004) discovered that 
BMAA can also be incorporated into proteins in samples, and requires hydrolysis to 
release the amino acid from its bound form.  The discovery of protein incorporation 
accounted for an underestimation of BMAA in biological samples in previous studies.       
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Faasen, et al. (2012) compared three analytical techniques, HPLC-FLD and LC-
MS/MS using derivatized and underivatized samples (Faasen et al., 2012).  Following the 
literature of comparative analytical methods of BMAA analysis in the present study, LC-
MS/MS using derivatized samples (to reduce polarity), or underivatized samples, proved 
to be more accurate than HPLC-FLD, on the basis of its higher selectivity: four different 
selective criteria are required rather than the two required by HPLC-FLD (Faasen et al., 
2012).  The two selectivity criteria required for HPLC include a fluorescent signal by 
derivatization with AQC (AccQ-Taq) (the derivatization method that makes the 
derivatives more stable than the original amino acids and adds a fluorescent tag for 
analysis), and retention time, whereas the four selective criteria of LC-MS/MS are 
retention time, two separate mass to charge ratios (m/z) based on precursor and product 
ions, and product ion abundance ratio (Faasen et al., 2012).  The lower selectivity of 
HPLC-FLD and LC-MS led to the detection of higher concentrations of BMAA than LC-
MS/MS, however, this was likely a result of lower selectivity and the false positives of 
other amino groups that fluoresced with AQC or other derivatization methods (Faasen et 
al., 2012).  There has been little research done between labs to use different published 
methods to analyze the same set of samples, therefore, creating many discrepancies 
between data sets.  There has yet to be a single method or interlaboratory evaluations of 
methods.  The magnitude of potential human exposure is still unknown therefore, because 
of the wide range of data.   
In a study done by Karlsson, et al. (2012) researchers used Matrix Assisted Laser 
Desorption Ionization – imaging mass spectrometry (MALDI-IMS) in an effort to image 
and study protein changes in the brains of adult rats after exposure to BMAA during the 
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neonatal period.  The instrumental method MALDI/IMS works by using dyes to 
accentuate proteins of interest, and by taking images at different stages, MALDI allows 
researchers to see protein changes (Karlsson et al., 2012).  Not only does MALDI-IMS 
provide spatial localization of multiple proteins, but this instrument has the capability to 
provide a rough estimate of the quantity of protein or analyte of interest in one location.  
Karlsson, et al. (2012) looked at different sections of brain tissue and saw multiple 
changes in proteins using this method.  The study by Karlsson, et al. (2012) in particular 
provided data suggesting that BMAA changes various proteins in the hippocampus along 
with neurodegenerative symptoms and neuronal cell apoptosis.   
Thus far, matrix assisted laser desorption time of flight mass spectrometry (MALDI-
ToF/ToF-MS/MS), has not been used for the quantitative analysis of BMAA, however, 
research has been done using MALDI-ToF/ToF-MS/MS to quantify other small 
molecules, including other amino acids (Alterman et al., 2004; Cohen et al., 2014; Dong 
et al., 2010; Gobey et al., 2005; Gogichaeva et al., 2006).  Both HPLC-FLD and LC-
MS/MS require extensive sample preparation, derivatization, acid hydrolysis, reverse-
phase elution for separation, and a data acquisition time of 27 minutes (Faasen et al., 
2012).  If MALDI-ToF-MS proves to be a successful method for the quantification and 
qualification of BMAA, it would reduce the time for sample preparation and data 
acquisition to only a few seconds per sample, provide high throughput analysis, and 
would eliminate the need for derivatization, chromatographic separation, and 
modification of amino acids (Gogichaeva et al., 2012).  Furthermore, coupling MALDI-
ToF-MS to MALDI-IMS could be innovative in terms of imaging the location of BMAA 
in biological systems while quantifying the concentrations in these locations. 
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1.3. BMAA AND ITS STRUCTURAL ISOMER DAB 
Banack et al. (2010) published a paper discussing a structural isomer of BMAA that 
often co-exists in nature.  This structural isomer, 2-4-diaminobutyric acid (DAB) has the 
same mass as BMAA (118.13 m/z), but has a different structure and fragment ions 
(Figure 3) (Banack et al., 2010).  The fragment ions of BMAA are 119 m/z to 102 m/z 
and 76 m/z, whereas the fragment ions for DAB are 119 m/z to 101 m/z and 74 m/z, 
respectively.  The co-occurrence of BMAA and DAB, and the inability for HPLC-FLD 
and LC-MS to distinguish the structural isomers could lead to overestimation of BMAA 
in a biological sample.  The amino acid DAB, is another non-protein amino acid that was 
first discovered, in a variety of antibiotics, as a bacterial metabolic product, and is 
commonly found in both prokaryotes and eukaryotes (Banack et al., 2010).  Since 2010, 
many research groups have successfully separated BMAA from DAB to provide more 
accurate data on the quantitation of BMAA in biological samples.      
 
 
Figure 3. Chemical structures of β-N-methylamino-L-alanine (BMAA) and its structural 
isomer 2-4-diaminobutyric acid (DAB) 
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1.4. LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY  
Chromatography, whether it be liquid or gas, is the separation of a mixture or solution 
based on three interactions: the mobile phase, the stationary phase, and the analytes 
within the mixture.  Liquid chromatography uses a liquid mobile phase, as the name 
suggests, and carries the mixture through a column that contains a stationary phase.  
Within this column, the analytes in the mixture interact with the stationary phase, passing 
through the column at different times.  The relative affinity of the analyte to the 
stationary phase determines the time in which it will elute, or its retention time.  On the 
basis of an analytes chemical structure and polarity, it will interact differently with the 
mobile phase and surface of the stationary phase.  These differences in interaction, result 
in different retention times of components in a mixture.  Liquid chromatography is 
commonly used in the study of natural products and toxins. 
The type of mobile phase must be carefully selected.  Common mobile phases used in 
liquid chromatography are acetonitrile, dioxane, ethanol, methanol, isopropanol, 
tetrahydrofuran, and water (Buszewski et al., 2012). Additives such as formic acid may 
be mixed into water or acetonitrile to shift the polarity of the mobile phase (Buszewski et 
al., 2012).  For the analysis of BMAA, multiple mobile phases have been used, but are 
also dependent on the stationary phase of the column (Table 2).  Table 2, illustrates 
common mobile phases that have been used for the study of BMAA in biological 
samples, along with chromatographic columns that have been used for each mobile 
phase.  For the study of amino acids, particularly BMAA, a combination of acetonitrile, 
water, and a dilute acid is typically used (Murch et al., 2004).   
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The column used for amino acid analysis is dependent on the mobile phase, 
composition and polarity of the analyte, derivatization, and whether positive or negative 
mode is used.  Research groups who have used AQC derivatization, typically use a C18 
column, whereas groups who analyze BMAA in its natural form, or underivatized, 
typically use a hydrophilic Interaction liquid chromatography (HILIC) column.     
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Table 2. Methods of detection and quantitation of BMAA in biological samples in current literature.  
Reference Analytical 
Quantitation 
Method 
Derivatiza
tion 
Method 
Column ID Mobile Phase Instrument 
 
Murch (2004) LC-MS & 
HPLC-FLD 
AQC Waters Nova-Pak C18 140mM sodium acetate, 
5.6mM trimethylamine pH 5.2 
(mobile phase A), 60% ACN 
in water (mobile phase B) 
Agilent liquid 
chromatography 
mass spectrometer, 
single quad, DAD 
Rosen (2008) LC-MS/MS NONE Zic®-HILIC (5μm, 
50x2.1mm) 
ACN and 60mM FA in water Micromass Quattro 
Ultima or API 
4000 QTRAP and 
Waters Alliance 
2690 or Agilent 
1100 
Faassen (2009) LC-MS/MS NONE Zic®-HILIC (5μm, 
2.1x150mm) 
65% ACN, 35% water and 
0.1% FA 
Agilent 1200 LC 
and an Agilent 
G6410A QQQ 
Spacil (2010) LC-MS/MS AQC Hypersil GOLD C18 0.1% FA in water and ACN 
(93:7) (mobile phase A), 0.1% 
FA in ACN (mobile phase B) 
API 2000™ LC-
MS/MS QQQ 
Brand (2010) LC-MS/MS AQC Thermo Hypersil 
GOLD 
(100mmx2.1mm, 3μm 
particle column) 
0.1% FA in water (mobile 
phase A), 0.1% FA in ACN 
(mobile phase B) 
QQQ, Waters 2475 
Multi-λ-
Fluorescence 
Detector 
Esterhuizen-
Londt (2011) 
LC-MS EZ: 
faast™ 
amino acid 
analysis kit 
Phenomenex AAA-
MS 250x2.0mm 
10mM ammonium formate in 
water (mobile phase A), 
10mM ammonium formate in 
methanol (mobile phase B) 
Shimadzu LC 
20AB and 
Shimadzu 2010 
EV 
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Christensen 
(2012) 
LC-MS/MS AQC Waters Xbridge 
4.6x150mm C18 
column 
Proprietary Waters AccQ-Tag 
Ultra Eluents 
Agilent 
Technologies 1200 
LC with an Agilent 
Technologies 
G6410A QQQ 
Glover (2012) LC-TOF-MS AQC Waters amino acid 
analysis column 
(100x2.1mm; 1.7μm, 
C18) 
0.1% FA in water (mobile 
phase A), ACN (mobile phase 
B) 
Single quadrapole 
mass spectrometer 
(Waters EMD 
1000) TOF-MS; 
Waters LCT 
Premier 
Faassen (2012) LC-MS/MS 
(derivatized 
and 
underivatized) 
and HPLC-
FLD 
NONE and 
AQC 
LC-MS/MS: 
(derivatized) Zorbax 
Eclipse AAA 
(4.6x75mm, 3.5μm 
column) 
(underivatized) Zic®-
HILIC (2.1x150mm, 
5μm diameter column) 
HPLC-FLD: Nova-
Pak C18 (3.9x300mm, 
4μm column) 
LC-MS/MS: ACN with 0.1% 
FA (mobile phase A), 
Millipore water and 0.1% FA 
(mobile phase B) 
HPLC-FLD: 140mM sodium 
acetate and 5.6mM 
trietylamine in Millipore water 
pH 5.2 (mobile phase A), 
ACN (mobile phase B), 
Millipore water (mobile phase 
C) 
LC-MS/MS: 
Agilent 1200LC 
and Agilent 6401A 
QQQ  
HPLC-FLD: 
Agilent 1100 LC-
FLD 
Mondo (2012) LC-MS/MS 
and HPLD-
FLD 
AQC Waters Nova-Pak C18 
column 
(3.9mmx300mm) 
LC-MS/MS: Aqueous 0.1% 
FA (mobile phase A), 0.1% 
FA in ACN (mobile phase B) 
HPLC-FLD: 140mM sodium 
acetate, 5.6mM trietylamine, 
pH 5.2 (mobile phase A), 52% 
ACN in water (mobile phase 
B) 
LC-MS/MS: 
Triple quadrupole 
system 
HPLC-FLD: 
Waters 2475 Multi 
λ-Fluorescence 
Detector 
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Jiang (2012) LC-MS/MS AQC HPLC: Hypersil 
GOLD C18 column 
(100x2.1mm, 3μm 
particle size) 
UHPLC: Agilent 
Bonus RP Rapid 
Resolution High 
Throughput (RRHT) 
column (100x2.1mm, 
1.8μm particle size) 
HPLC: 5% ACN in water 
with 0.3% acetic acid and 
0.0005% TFA (mobile phase 
A), ACN with 0.3% acetic acid 
and 0.005% TFA (mobile 
phase B) 
UHPLC: 0.1% FA in water 
(mobile phase A), 0.1% FA in 
ACN (mobile phase B) 
Triple quadrupole 
system 
Jiang (2013) LC-MS/MS AQC ACCQ-TAG™ 
ULTRA C18 column 
(100x2.1mm, 1.7μm 
particle size) 
5% ACN in water with 0.3% 
acetic acid (mobile phase A), 
ACN with 0.3% acetic acid 
(mobile phase B) 
TSQ Vantage 
triple quadrupole 
mass spectrometer 
Dunlop (2013) LC-MS/MS AQC Waters AccQTag 
Ultra C18 column 
(2.1x100mm) 
Aqueous 0.1% FA (mobile 
phase A), and 0.1% FA in 
ACN (mobile phase B) 
Thermo Scientific 
Finnigan TSQ 
Quantum UltraAM 
tandem mass 
spectrometer QQQ 
Masseret 
(2013) 
LC-MS/MS AQC Waters AccQTag 
Ultra column 
(2.1x100mm) 
Aqueous 0.1% FA (mobile 
phase A), 0.1% FA in ACN 
(mobile phase B) 
Thermo Scientific 
Finnigan TSQ 
Quantum Ultra 
AM tandem mass 
spectrometer QQQ 
Faassen (2013) LC-MS/MS NONE ZIC®-HILIC column 
(2.1x150mm, 5μm 
diameter) 
ACN with 0.1% FA (mobile 
phase A), Millipore water with 
0.1% FA (mobile phase B) 
Agilent 1200 LC 
and an Agilent 
6410A QQQ 
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Karlsson 
(2014) 
LC-MS/MS AQC ACCQ-TAG™ 
ULTRA C18 column 
(100mmx2.1mm, 
1.7μm particle size 
column) 
5% ACN in water with 0.3% 
acetic acid (mobile phase A), 
ACN with 0.3% acetic acid 
(mobile phase B) 
TSQ Vantage 
QQQ 
Mondo (2014) LC-MS/MS 
and HPLC-
FLD 
AQC LC-MS/MS: BEH 
C18 column 
(150x2.1mm, 1.7μm) 
HPLC-FLD: Waters 
Nova-Pak C18 column 
(3.9x300mm) 
LC-MS/MS: 20mM 
ammonium formate with 0.2% 
FA (mobile phase A), 0.1% 
FA in ACN (mobile phase B) 
HPLD-FLD: 140mM sodium 
acetate, 5.6mM 
trimethylamine, pH 5.7 
(mobile phase A), 52@ 
aqueous ACN (mobile phase 
B) 
LC-MS/MS: 
Waters Acquity I-
Class UPLC 
system 
HPLC-FLD: 
Waters 1525 
Binary HPLC, 
Waters 2475 Multi 
λ-Fluorescence 
detector 
Banack (2014) LC-MS/MS AQC Waters AccQ Tag 
Ultra column 
(2.1x100mm) 
0.1% FA in water (mobile 
phase A), 0.1% FA in ACN 
(mobile phase B) 
Waters Acquity-
UHPLC and 
Thermo TSQ QQQ 
Jiao (2014) LC-MS/MS AQC Eclipse XDB-C18 
column (4.6x100mm) 
28% ACN in water with 0.1% 
NH4COOH 
Agilent 1290/6460 
HPLC/MS/MS 
spectrometry 
system with ESI 
Baptista (2015) LC-MS/MS NONE ZIC-HILIC 
(2.1x100mm, 5μm 
diameter) column 
ACN with 0.1% FA (mobile 
phase A), Deionized water 
with 0.1% FA (mobile phase 
B) 
Thermo LCQ Fleet 
Ion Trap LC-MS 
system 
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1.5. HYDROPHILIC INTERACTION LIQUID CHROMATOGRAPHY 
(HILIC) 
 
The HILIC column was first developed and published in by Linden et al. (1975).  
Hydrophilic interaction liquid chromatography (HILIC), is typically described as a 
variant on normal phase liquid chromatography in which the mobile phase used is less 
polar than the stationary phase (Buszewski et al., 2012).  Common stationary phases are 
similar to those utilized in normal phase liquid chromatography, such as, silica.  In 
contrast to normal phase liquid chromatography, HILIC employs a mobile phase that is 
often used in reverse phase liquid chromatography (Buszewski et al., 2012).  The use of 
HILIC has become more and more popular as this development allows for the analysis of 
small molecules in complex matrices and can be used for ion chromatography to analyze 
analytes that are positively or negatively charged (Buszewski et al., 2012).  There is some 
debate as to how retention is achieved using HILIC, however, the most current 
explanation described by Buszewski et al. (2012), is depicted below (Figure 4).  On the 
basis of Buszewski’s theory, separation is achieved by partitioning, or liquid/liquid 
extraction, per say (Buszewski et al., 2012).  With a mobile phase composed of 
acetonitrile and water, the water forms a layer on the surface of the very hydrophilic 
stationary phase (silica) (Buszewski et al., 2012).  The acetonitrile forms an additional 
layer on top of the aqueous layer (Buszewski et al., 2012).  This interaction creates a type 
of liquid/liquid attraction in which the analyte moves towards the hydrophilic stationary 
phase, being retained within the aqueous layer (Buszewski et al., 2012).  On the basis of 
the increasing hydrophilicity of the analyte, elution off of the stationary phase of the 
column will occur later, separating the analyte from the matrix.      
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Figure 4. Proposed mechanism of HILIC separation by Buszewski et al., 2012 (Buszewski et al, 
2012). 
 
1.6. MATRIX ASSISTED LASER DESORPTION IONIZATION (MALDI) 
Matrix assisted laser desorption ionization (MALDI), is an ionization technique that 
requires the sample to be placed in a matrix that protects the sample from being destroyed 
by a laser that is applied to the sample/matrix.  With MALDI-ToF-MS, a laser is applied 
to the sample/matrix, ionizing the sample and allowing the secondary ions to travel 
through the flight tube, separating them by mass and charge, and finally analyzing them 
by the ToF analyzer (Figure 5).  Quantitative amino acid analysis has been done using 
MALDI-ToF-MS/MS, however, no research has been published using these techniques 
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for the analysis of BMAA, and therefore, operating parameters had to be optimized for 
this particular amino acid.  Previous research has suggested that BMAA becomes 
misincorporated into human proteins by replacing L-serine, and in a study done by 
Dunlop, et al. (2013), data provided evidence for this misincorporation.  In a study done 
by Alterman, et al. (2004) at the University of Kansas, MALDI-ToF-MS/MS proved to 
be successful in the quantification and qualification of nineteen (19) amino acids using α-
cyano-4-hydroxycinnamic acid (CHCA) as the matrix.  Other matrices used in this study 
included meso-tetra (pentafluorophenyl) porphine (F20TTP), and 2,5-dihydroxybenzoic 
acid (DHB), however, with F20TTP and DHB, only 13 and 14 of the amino acids were 
observed, respectively (Alterman et al., 2004).  Serine was not observed using DHB.  On 
the basis of the success of this previous study, CHCA was the matrix of choice for the 
analysis of BMAA using MALDI-ToF-MS/MS, in addition to the data showing strong 
evidence that BMAA is capable of replacing L-serine (Alterman et al., 2004).  For the 
analysis of amino acids, 1μL of CHCA is typically spotted onto each sample well, and 
allowed to dry.  Once dry, 1μL of sample is spotted onto each sample well on top of the 
dried matrix.  The plate is then allowed to air dry, and is then placed into the holder of the 
MALDI instrument.     
As discussed by Gogichaeva, et al. (2012), the use of MALDI-ToF/ToF-MS/MS as a 
qualitative and quantitative method for amino acid analysis, has many advantages over 
liquid chromatography.  The MALDI-ToF/ToF-MS/MS decreases the data acquisition 
time to only a few seconds as opposed to the data acquisition time using LC-MS/MS of 
30-45 minutes.  This research group also determined that MALDI-ToF/ToF-MS/MS is 
capable of distinguishing structural isomers (Gogichaeva et al., 2012).  Derivatization and 
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chromatographic separation is not necessary with MALDI-ToF-MS, however, many 
methods using HPLC and LC-MS/MS require both.   
 
Figure 5. Schematic diagram of MALDI-ToF-MS/MS instrument in reflector mode. 
Figure 5 is a rudimentary diagram illustrating a MALDI-ToF-MS instrument used in 
reflector mode.  Using reflector mode, the sample has more time in the flight tube, 
allowing for greater separation of a mixture, to differentiate between isobaric and 
isomeric isotopes.  In linear mode, isomers cannot be distinguished from each other, and 
can lead to an overestimation of an analyte if an isomer is present in the sample.   
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1.7. SPECIFIC AIMS 
The main objective of this research included laboratory experiments to develop a 
quantitative MALDI-TOF/TOF-MS/MS method to detect and quantify BMAA in a 
variety of matrices.  Through a series of aims, the main objective was achieved.  The 
aims presented in this study are described as follows: 
i. Adapt/develop an LC-MS/MS method to detect and quantify BMAA in a 
variety of matrices 
ii. Develop a MALDI-TOF/TOF-MS/MS method to detect and quantify 
BMAA in a variety of matrices 
iii. Synthesize 13C-BMAA to use as an internal standard for both the 
MALDI-TOF/TOF-MS/MS and LC-MS/MS method 
iv. Compare quantitative results from LC-MS/MS to that of MALDI-
TOF/TOF-MS/MS 
v. Apply MALDI-TOF/TOF-MS/MS method to biological samples in 
search of BMAA incorporation 
2. MATERIALS AND SAMPLE PREPARATION 
2.1. MATERIALS  
 Reference standards of L-BMAA hydrochloride was purchased from Sigma 
Aldrich (St. Louis, MO), and DL-2,4-DAB dihydrochloride was purchased from Alfa 
Aesar (Ward Hill, MA).  Amino Acid Standard (AAS) was purchased from Sigma 
Aldrich (St. Louis, MO) in a solution of 0.1 N HCl (Table 2).  Methyltyrosine was 
purchased from Sigma Aldrich (St. Louis, MO).  Bovine Serum Albumin (BSA) was 
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purchased from Sigma Aldrich (St. Louis, MO).  The 13C-BMAA was prepared in house 
according to a D3-BMAA synthesis by Jiang, et al. (2013) with some modifications (see 
below).  Acetonitrile, HCl, HPLC grade water, and chloroform were purchased from 
Fisher Scientific (Fair Lawn, NJ).  Biological tissue samples were provided by Dr. Larry 
Brand (Division of Marine Biology and Fisheries, Rosentiel School of Marine and 
Atmospheric Science) in 2012, from the Johnson Key Basin, Florida.  The standard stock 
solutions of both BMAA and DAB in powder form were prepared with HPLC grade 
water at 10mg/mL for BMAA and 1mg/mL for DAB, respectively.  These stock solutions 
were diluted to varying concentrations dependent on sample.  For methodology, please 
see Chapters 3 and 4. 
 The matrices, AAS, BSA, and biological tissue samples, were chosen for this 
research to demonstrate the validity of a MALDI-TOF/TOF-MS/MS method when 
spiking samples in increasingly complex matrices.  The biological tissue samples 
(shrimp) provide an example of biological tissues from an aquatic system where the 
presence of BMAA has been seen in previous studies.     
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Table 3. Amino Acid Standard Composition 
AMINO ACID MOLECULAR 
FORMULA 
CONCENTRATION 
(μMoles/mL) 
MOLECULAR 
WEIGHT 
L-Alanine C3H7NO2 2.50 89.09 
Ammonium 
Chloride 
NH4Cl 2.50 53.49 
L-Arginine C6H14N4O2 2.50 174.2 
L-Aspartic Acid C4H7NO4 2.50 133.1 
L-Cystine C6H12N2O4S2 1.25 240.3 
L-Glutamic Acid C5H9NO4 2.50 147.1 
Glycine C2H5NO2 2.50 75.07 
L-Histidine C6H9N3O2 2.50 155.2 
L-Isoleucine C6H13NO2 2.50 131.2 
L-Leucine C6H13NO2 2.50 131.2 
L-Lysine C6H14N2O2 2.50 146.2 
L-Methionine C5H11NO2S 2.50 149.2 
L-Phenylalanine C9H11NO2 2.50 165.2 
L-Proline C5H9NO2 2.50 115.1 
L-Serine C3H7NO3 2.50 105.1 
L-Threonine C4H9NO3 2.50 119.1 
L-Tyrosine C9H11NO3 2.50 181.2 
L-Valine C5H11NO2 2.50 117.2 
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2.2. SAMPLE PREPARATION 
2.2.1. SYNTHESIS OF 13C-BMAA 
The synthesis of 13C-BMAA was performed according to a D3-BMAA synthesis 
by Jiang (2013) with some modifications.  Sodium hydroxide (0.22g) was added to a 
room temperature solution of (0.25g) 13C-methylamine hydrochloride in 1mL HPLC 
grade water and stirred until dissolved.  Two-Acetamidoacrylic acid (0.0925g) was then 
added to the solution and stirred at room temperature for 10 minutes.  The mixture was 
then stirred for 22 hours at 35°C.  The mixture was cooled back down to room 
temperature and the solution was placed in a rotary evaporator to remove methylamine.  
The crude product was dissolved in excess 3M HCl (2.0mL), and refluxed for 2 hours at 
100°C.  After refluxing, the sample was placed in a vacuum centrifuge to remove HCl in 
vacuo.  The product was recrystallized in an ice bath (~4°C) using ethanol and water.  
The crystals were then filtered and washed with cold ethanol four times, and then dried 
under vacuum.  The final yield of 13C-BMAA was 169.5mg.  The NMR spectral data is 
consistent with the desired outcome (Figure 7).   
 
 
Figure 6. Proposed mechanism of 13C-BMAA 
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Figure 7. 1H-NMR spectra of unlabeled BMAA (top figure) and 13C-BMAA (bottom 
figure).  The singlet peak at 3.083 ppm is absent in the unlabeled BMAA. 
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2.2.2. MALDI MATRIX 
The α-Cyano-4-hydroxycinnamic acid (CHCA) matrix was prepared according to 
Gogichaeva et al. (2012) without recrystallization, because of a higher purity compound 
that has become available since the publication of the paper.  A solution of 8.5mL ACN, 
2.47mL water, and 30μL of 10% trifluoroacetic acid was prepared.  A 1mL aliquot of this 
solution was placed in a 1.5mL vial and CHCA (powdered form) was added until 
saturation.  The solution was prepared fresh each day of analysis to ensure no degradation 
of the matrix.   
2.2.3. STANDARDS FOR METHOD DEVELOPMENT 
Stock solutions with concentrations of 1mg/mL (1000ppm) of BMAA and DAB 
were prepared in HPLC grade water and used for the standard calibration curve, and to 
spike AAS, BSA, and biological tissue homogenates for method development.  The stock 
solutions were diluted to different concentrations depending on the analysis.  The 
structural isomer DAB, was used as an internal standard for MALDI-TOF/TOF-MS/MS.  
Validation procedures were done using BMAA and DAB standards.   
2.2.4. BMAA AND AMINO ACID STANDARDS 
Stock solutions, 1mL of 100μM AAS were prepared and spiked with 200μM of 
methyltyrosine as an internal standard (IS) and increasing concentrations of BMAA (0, 
20, 50, 100, and 300μM).  The solutions were prepared using HPLC grade water and 
stored in a refrigerator at 4°C until analysis. 
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2.2.5. BMAA AND BOVINE SERUM ALBUMIN 
Two methods of hydrolysis were employed for the analysis of BSA as part of 
methods development, and subsequent analysis of tissue samples.  In the first method, a 
microwave-assisted acid hydrolysis was used.  According to previous literature, this 
method of hydrolysis vastly reduces the hydrolysis time, while still providing comparable 
digestion of proteins (Zhong et al., 2004).  For development of this method, 10μL 
(1μg/1μL) of aqueous BSA solution was combined with 10μL of 20mM Dithiothreitol 
(DTT), varying concentrations of BMAA (0, 20, 50, 100, 120, and 300μM) and constant 
concentration of DAB (IS) (100μM) in 1.5mL polypropylene Eppendorf tubes (6 tubes).  
The tube was then capped, sealed with tephlon tape and incubated for 20 minutes at 
60°C.  Once this was complete, the tape was removed and 20μL of 50% (vol/vol) 
trifluoroacetic acid (TFA) was added.  The Eppendorf tubes were resealed, and placed in 
a round bubble rack floating in at least 100mL of distilled water in a round polypropylene 
container (Figure 8).  The samples were then irradiated for 7.5 minutes in 900 watt 
microwave.  Once irradiation was complete, samples were dried in vacuo using a 
Speedvac at 45°C, and then resuspended in 50μL of 0.1% aqueous formic acid.  The 
samples were centrifuged at 14,000rpm for 5 minutes to remove particulate matter and 
the supernatant was stored at 4°C until analysis with MALDI-TOF/TOF-MS/MS.  For 
analysis, 1μL of CHCA matrix was spotted onto the MALDI plate, allowed to dry, and 
then 1μL of BSA sample was spotted on top of the dried matrix.  Each sample was 
analyzed and assayed in duplicate.     
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Figure 8. Microwave-assisted acid hydrolysis set-up 
 
For the second method of hydrolysis, a more traditional hydrolysis was employed.  
Bovine serum albumin (BSA) (0.5g) was weighed out and transferred to 10mL of 6M 
HCl and hydrolyzed for 24 hours at 110°C.  After hydrolysis, the sample was filtered 
using vacuum filtration (Whatman 42.5mm 0 circles, 11μm porosity), and further filtered 
with a 25mm syringe filter (Fisherbrand, 0.2μm, PTFE, Non-sterile).  The filtered extract 
was then transferred to a 25 mL round bottom flask and attached to a rotary evaporator 
(BUCHI Rotovapor R-3, Recirculating Chiller F-100, and Vacuum Pump V-700) with 
the water bath set at 65°C until dry.  The residue was resuspended in 10 mL of HPLC 
grade water, and washed with 10 mL of chloroform.  The organic layer was discarded, 
and the aqueous layer was placed into a 25 mL glass vial and stored at 4°C until analysis.  
Samples (40μL) were prepared containing 20μL of CHCA matrix, BSA solution, and 
varying concentrations of BMAA and 50ppm DAB (IS).  The concentrations for BMAA 
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were 0, 10, 25, 50, 75, and 125ppm.  Each sample (2μL) was spotted onto a MALDI plate 
with two spots for each concentration.  All BSA samples were analyzed in duplicate and 
quantitation of BMAA was done using MALDI-TOF/TOF-MS/MS. 
2.2.6. ANALYSIS OF BIOLOGICAL TISSUES 
Biological tissues (shrimp), were collected by Larry Brand in 2011 from the 
Johnson Key Basin, ENP, Florida.  The tissues were stored in ethyl alcohol prior to 
extraction procedures.  Tissues were soaked in 500mL MilliQ water for an hour to wash.  
Tissue samples were then submerged in liquid nitrogen and homogenized using a 
sterilized food processor.  Tissue homogenates (1g) were hydrolyzed in 10mL of 6M HCl 
for 24 hours at 110°C (Figure 9).  After hydrolysis, particulate matter was removed using 
vacuum filtration (Whatman 42.5mm 0 circles, 11μm porosity) and further filtered with 
25mm syringe filters (Fisherbrand, 0.2μm, PTFE, Non-sterile).  Filtered extract was 
transferred into ten 1.5mL Eppendorf tubes, 1mL aliquots per tube.  The samples were 
dried in vacuo using a Speedvac at 45°C.  The samples were then spiked with increasing 
concentrations of BMAA (0, 1, 10, 75, and 200ppm) and resuspended to 1mL with 0.1% 
aqueous formic acid.  To remove any residual lipids prior to analysis, the resuspended 
extract was washed with 500µL of chloroform.  The chloroform layer was then discarded.  
Further, a solid-phase extraction (SPE) method developed by Li et al., in 2012 was 
adapted for these biological samples (Li et al., 2012).   Phenomenex Strata-X-C SPE 
33µm Polymeric Strong Cation, 200mg/6mL cartridges were used for an SPE clean-up.  
The columns were activated with 5mL of methanol, followed by 5mL of 0.1% formic 
acid.  The samples (1mL) were then applied to the columns.  The samples were washed 
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again with 5mL of 1% formic acid, and then 5mL of methanol.  Finally, the analyte was 
eluted with 5mL of NH4OH v/v in methanol and collected in clean, 8mL glass vials.  The 
samples were then dried under nitrogen and resuspended in 1mL of HPLC grade water.  
Each sample was spiked with 25ppm of DAB as an internal standard (IS).  The samples 
were stored at -4°C until analysis.  A schematic of the sample preparation can be seen in 
Figure 10.  All biological tissue samples were analyzed and assayed in triplicate.  
Quantitation of BMAA was performed using MALDI-TOF/TOF-MS/MS and the method 
of standard addition.     
a  
Figure 9. Acid Hydrolysis Apparatus 
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Figure 10. Sample preparation schematic of biological tissues with a solid phase 
extraction clean-up for the quantitative analysis of BMAA by MALDI-TOF/TOF-
MS/MS. 
 
3. ANALYSIS BY LC-MS/MS  
3.1. INSTRUMENTAL PARAMETERS  
The LC-MS/MS analysis was performed using a Shimadzu Prominence LC-
20AD Ultra-Fast Liquid Chromatograph combined with an AB Sciex QTRAP 5500 
Triple-Quadrupole mass spectrometer, equipped with a Turbospray ESI source supplied 
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with nitrogen gas.  The BMAA was separated from other amino acids using hydrophilic 
interaction chromatography (HILIC).  A binary gradient system was used with 0.1% 
formic acid dissolved in HPLC grade water (mobile phase A), and 0.1% formic acid in 
acetonitrile (mobile phase B) with a flow rate of 0.5mL/min.  The column temperature 
was set at 40°C, while the auto sampler temperature was set at 15°C.  The elution 
gradient (10 minutes) was as follows: time 0 = 30% A; 0.5min. = 30% A; 5min. = 95% 
A; 6.25min. = 95% A; 6.5min. = 5% A; 8min. = 5% A; 8.25min. = 30% A; 10min. = 
30% A.  Separation was achieved using a Phenomenex Kinetex HILIC 100 x 4.6mm, 
2.6μm particle size column.  The mass spectrometer was operated in positive mode.  The 
source temperature was 600°C and the ESI spray voltage was set at 5,500V.  Each of the 
following values are arbitrary, however, the auxiliary gas setting was 40, the nebulizer 
gas setting was 60, and the curtain gas setting was 30. 
The protonated molecular ion of BMAA (119.033 m/z) was used as the parent ion 
for multiple reaction monitoring (MRM) analysis.  The following transitions were 
monitored: 119>102 (collision energy of 15V) and 119>76 (collision energy 17V).  The 
analyte BMAA, was successfully separated from its isomer DAB and 13C-BMAA.  As 
seen in figure 11, with this LC-MS/MS method, for the first transition (BMAA 119>102, 
DAB 119>101, and 13C-BMAA 120>103), BMAA elutes at 5.6 minutes, whereas DAB 
elutes at 5.54 minutes, and 13C-BMAA elutes at 5.49 minutes.  Peak area and intensity 
values for each analysis were exported to Microsoft Excel and processed.  Analyses were 
done at the Advanced Mass Spectrometry Facility at Florida International University.   
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Figure 11. LC-MS/MS spectra of BMAA, DAB, and 13C-BMAA standards. 
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3.2. RESULTS/DISCUSSION 
3.2.1. ANALYSIS OF STANDARDS 
Varying concentrations of BMAA (0, 0.05, 0.1, 0.25, 0.5, and 1.0ppm) were 
spiked with 1ppm of 13C-BMAA and 1ppm of DAB.  Both DAB and 13C-BMAA were 
used as internal standards to determine which would provide a better linearity.  Multiple 
linear regressions were performed and can be seen in Figures 12-15.  Figure 12 describes 
the linear regression of BMAA with 13C-BMAA as the internal standard from the first 
transition of 119.033>102.2 m/z for BMAA and 120.062>103.1 m/z.  The analyte, 
BMAA, was expected to elute at 5.49 minutes, whereas 13C-BMAA was expected to elute 
at 5.47 minutes.  Further, Figure 13 describes the linear regression of BMAA again 
with 13C-BMAA as the internal standard with a different transition.  The transition used 
for BMAA was 119.033>76.1 m/z, whereas the transition for 13C-BMAA was 
120.062>103.1 m/z (Figure 13).   
Figure 14 shows the linear relationship between BMAA with DAB as the internal 
standard from the first transition of 119.033>102.2 m/z for BMAA and 119.033>101.2 
m/z for DAB.  The analyte, BMAA, was expected to elute at 5.49 minutes, whereas DAB 
was expected to elute at 5.52 minutes for this particular transition.  Figure 15 also shows 
the linear relationship of BMAA with DAB as the internal standard, but with the 
transitions of 119.033>76.1 m/z  for BMAA and 119.033>101.2 m/z for DAB.  The 
particular transition just described, provided the greatest linearity with an R2 value of 
0.9999.  The chromatograms are shown in Figures 16-23 for the calibration standards and 
amino acid mixtures.   
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Figure 12. Representative LC-MS/MS calibration curve for the concentration ratios of BMAA 
to 13C-BMAA (IS) in ppm against the peak area ratios of BMAA to 13C-BMAA (IS).  The 
transitions for BMAA and 13C-BMAA are 119.03>102.2 m/z and 120.062>103.1 m/z, 
respectively.  
 
 
Figure 13. Representative LC-MS/MS calibration curve for the concentration ratios of BMAA 
to 13C-BMAA (IS) in ppm against the peak area ratios of BMAA to 13C-BMAA (IS).  The 
transitions for BMAA and 13C-BMAA are 119.03>76.1 m/z and 120.062>103.1 m/z, 
respectively.  
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Figure 14. Representative LC-MS/MS calibration curve for the concentration ratios of BMAA to 
DAB (IS) in ppm against the peak area ratios of BMAA to DAB (IS).  The transitions for BMAA 
and DAB are 119.033>102.2 m/z and 119.033>101.2 m/z, respectively.  
 
 
Figure 15. Representative LC-MS/MS calibration curve for the concentration ratios of BMAA to 
DAB (IS) in ppm against the peak area ratios of BMAA to DAB (IS).  The transitions for BMAA 
and DAB are 119.033>76.1 m/z and 119.033>101.2 m/z, respectively.  
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3.2.2. ANALYSIS OF BMAA IN AMINO ACID MATRIX 
Varying concentrations of BMAA (0, 0.1, and 0.25) were spiked with 1ppm 
of 13C-BMAA and 1ppm of DAB in a 50ppm amino acid solution.  Using the calibration 
curves above, the fourth linear regression was used to calculate the concentration of 
BMAA in each amino acid mixture.  The peak areas from the BMAA transition of 
119.003>76.1 m/z and DAB transition of 119>101.2 m/z of each spiked sample were 
exported to Microsoft Excel where they were processed.  The peak area ratios of BMAA 
to DAB were calculated for each sample and then substituted into the linear regression 
equation from Figure 15.  From the calculated value, percent recovery was then 
calculated using the equation.  
%𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 =  𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 − 𝐶𝐶𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑏𝑏𝐶𝐶𝐶𝐶𝑏𝑏𝑏𝑏
𝐶𝐶𝑠𝑠𝑠𝑠𝑠𝑠𝑏𝑏𝐶𝐶𝐶𝐶
 
 
The calculated concentration from the 0.1ppm spike was 0.102ppm which led to a 
% recovery of 102%.  The calculated concentration from the 0.25ppm spike was 
0.248ppm which led to a percent recovery of 99.2%.  The calibration using the 
isotopically-labeled standard 13C-BMAA was not successful and those transitions could 
not be calculated with the amino acid mixture samples.  The chromatograms are shown in 
Figures 16-23 for the calibration standards and the amino acid mixtures. 
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Figure 16. Chromatograms of water blanks, 0ppm BMAA and 0.05ppm BMAA standards with 
1ppm spikes of 13C-BMAA and DAB as internal standards. BMAA transitions 119.033>102.2 
m/z and 119.033>76.1 m/z and 13C-BMAA transition 120.062>103.1 m/z are shown above. 
Compliments of the Advanced Mass Spectrometry Facility, FIU. 
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Figure 17. Chromatograms of 0.1ppm, 0.25ppm, and 0.5ppm BMAA standards with 1ppm spikes 
of 13C-BMAA and DAB as internal standards. BMAA transitions 119.033>102.2 m/z and 
119.033>76.1 m/z and 13C-BMAA transition 120.062>103.1 m/z are shown above. Compliments 
of the Advanced Mass Spectrometry Facility, FIU. 
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Figure 18. Chromatograms of 0ppm and 1ppm BMAA standards with 1ppm spikes of 13C-BMAA 
and DAB as internal standards and 0ppm BMAA in an amino acid matrix with the same 
concentrations of internal standards (13C-BMAA and DAB). BMAA transitions 119.033>102.2 
m/z and 119.033>76.1 m/z and 13C-BMAA transition 120.062>103.1 m/z are shown above. 
Compliments of the Advanced Mass Spectrometry Facility, FIU. 
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Figure 19. Chromatograms of 0.1ppm, 0.25, and 0.5ppm BMAA in an amino acid matrix with 
1ppm spikes of both internal standards (13C-BMAA and DAB). BMAA transitions 
119.033>102.2 m/z and 119.033>76.1 m/z and 13C-BMAA transition 120.062>103.1 m/z are 
shown above. Compliments of the Advanced Mass Spectrometry Facility, FIU. 
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Figure 20. Chromatograms of water blank, 0.0ppm and 0.05ppm BMAA standards with 1ppm 
spikes of 13C-BMAA and DAB as internal standards. BMAA transitions 119.033>102.2 m/z and 
119.033>76.1 m/z and DAB transition 119.033>101.2 m/z are shown above. Compliments of the 
Advanced Mass Spectrometry Facility, FIU. 
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Figure 21. Chromatograms of 0.1ppm, 0.25ppm and 0.5ppm BMAA standards with 1ppm spikes 
of 13C-BMAA and DAB as internal standards. BMAA transitions 119.033>102.2 m/z and 
119.033>76.1 m/z and DAB transition 119.033>101.2 m/z are shown above. Compliments of the 
Advanced Mass Spectrometry Facility, FIU. 
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Figure 22. Chromatograms of 0ppm and 1ppm BMAA standards with 1ppm spikes of 13C-BMAA 
and DAB as internal standards and 0ppm BMAA in an amino acid matrix with the same 
concentrations of internal standards (13C-BMAA and DAB). BMAA transitions 119.033>102.2 
m/z and 119.033>76.1 m/z and DAB transition 119.033>101.2 m/z are shown above. 
Compliments of the Advanced Mass Spectrometry Facility, FIU. 
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Figure 23. Chromatograms of 0.1ppm, 0.25, and 0.5ppm BMAA in an amino acid matrix with 
1ppm spikes of both internal standards (13C-BMAA and DAB). BMAA transitions 
119.033>102.2 m/z and 119.033>76.1 m/z and DAB transition 119.033>101.2 m/z are shown 
above. Compliments of the Advanced Mass Spectrometry Facility, FIU. 
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3.3. CONCLUSIONS 
The LC-MS/MS data in chapter 3 are in agreeance with current literature using a 
HILIC column and underivatized BMAA.  The developed method on the AB Sciex 
QTRAP 5500 Triple-Quadrupole mass spectrometer successfully separated BMAA from 
its structural isomer DAB.  By using DAB as an internal standard, exceptional linearity 
was achieved.  As previously reported in literature, DAB tends to co-occur with BMAA 
in nature.  With successful separation of the isomers, using DAB as an internal standard 
proves to be a valuable internal standard for the quantitation of BMAA.  To date, I am 
unaware of DAB being used as an internal standard.   
The use of 13C-BMAA as an internal standard was unsuccessful.  In the 
chromatogram for 0ppm BMAA in Figure 16, a peak for BMAA still appeared, however, 
this peak is not present in the water blank that was injected prior to and after the samples.  
This peak indicates that the 13C-BMAA that was synthesized is not isotopically pure and 
did not get completely labeled during the synthesis.     
4. ANALYSIS BY MALDI-TOF/TOF-MS/MS 
4.1. INSTRUMENTAL PARAMETERS 
The MALDI-TOF/TOF-MS/MS analysis was performed using a Bruker Autoflex 
III Smartbeam MALDI-TOF/TOF-MS/MS.  All spectra were acquired using reflector 
mode and operated in positive ion mode.  The laser was set at 85% with a detector gain of 
25x (1,890V).  In order to cover as much of the target area as possible, the random walk 
mode was set to complete sample with 300 firing positions per spot, and 900 shots total 
per spectra.  The frequency of the laser was 200Hz which describes how many shots per 
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second occurred.  The sample rate was set to 2.00 GS/s for the highest resolution.  LIFT 
mode was used with the parent mass set to 119.14 Da.  The acquisition mode was set to 
fragments in order to differentiate between isomers.  Data was collected over the mass 
range of 80-143.  Two to three spots were prepared for each sample.  Analyses were done 
at the Advanced Mass Spectrometry Facility at Florida International University.   
Two methods of matrix deposition were utilized: a dried droplet approach, and a 
mixed droplet approach.  With the dried droplet approach, 1μL of CHCA matrix solution 
was deposited onto a MALDI plate in each individual wells (MTP 384 ground steel, ID 
210) (Figure 24).  Once dry, a 1μL aliquot of sample is deposited on top of the dried 
CHCA spot.  With the mixed droplet approach, equal parts of CHCA matrix and sample 
were combined and vortexed.  Once completely mixed, a 2μL aliquot of matrix/sample 
were deposited in each well. 
 
Figure 24. Image of 384 well MALDI Plate. 
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 Spectral data was exported to flexAnalysis Version 3.4 (Build 70) (Copyright © 
Bruker Daltonik GmbH) where the raw data was processed and peak height (intensity) 
and peak area values were determined.  The mass list values were then exported to 
Microsoft Excel where peak intensity or peak area was plotted against that of 
methytyrosine (IS) or DAB (IS).  Calibration curves were created for each of the different 
analyses (standards, amino acid matrix, BSA matrix, and biological tissue matrix).   
4.2. BMAA FULL SCAN ANALYSES 
4.2.1. FULL SCAN BMAA ANALYSIS  
Varying concentrations of BMAA (0, 20, 60, 800, 100, 200, and 300μM) 
were spiked with 200μM of methyltyrosine (IS).  The parent ion of BMAA is seen at 119 
m/z and the parent ion of the IS is seen at 196 m/z.  The spectra can be seen in figure 25.  
The mass list values for the peak intensity were exported to Microsoft Excel and the 
representative calibration curve can be seen in figure 26.  In full scan mode, successful 
separation of the BMAA standard and methytyrosine was accomplished.  The 
representative calibration curve gives an R2 value of 0.9881.  A higher R2 value could be 
obtained with more replicates. 
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Figure 25. Positive Ion MALDI-TOF-MS spectrum of BMAA and methyltyrosine (IS) with 
CHCA as the matrix.  BMAA Concentrations ranged from 0-300μM and methyltyrosine was at 
200μM.  The BMAA parent ion is seen at 119 m/z and the methyltyrosine parent ion at 196 m/z.  
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Figure 26. Representative calibration curve for the concentrations of BMAA in μM against the 
peak intensity ratios of BMAA to methyltyrosine (IS) with CHCA as the MALDI matrix.  Parent 
ions for BMAA and methyltyrosine were 119 and 196, respectively.  
 
4.2.2. FULL SCAN BMAA ANALYSIS IN AMINO ACID MATRIX 
An amino acid matrix was spiked with 200μM methyltyrosine (IS) and varying 
amounts of BMAA (0, 20, 50, 100, and 250μM).  All spectra were obtained using the 
same parameters.  Peak intensities and areas were exported to Microsoft Excel and 
processed.  This set of experiments was performed to determine if the developed 
MALDI-TOF-MS method could still successfully quantify BMAA in a more complex 
matrix.  The linear regression (Figure 27) of peak area intensities of BMAA vs. 
methyltyrosine (IS) provide good linearity, with a R2 value of 0.9997.  At the completion 
of this set of experiments, it was determined to continue with a MALDI-TOF/TOF-
MS/MS method to attempt to discriminate and quantify BMAA with the presence of one 
of its structural isomers, DAB.   
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Figure 27. Representative calibration curve for the concentrations of BMAA in μM against the 
peak intensity ratios of BMAA to methyltyrosine (IS) in an amino acid matrix, with CHCA as the 
MALDI matrix.  Parent ions for BMAA and methyltyrosine were 119 and 196, respectively.  
 
4.3. MALDI-TOF/TOF-MS/MS ANALYSES 
4.3.1. ANALYSIS OF STANDARDS 
Varying concentrations of BMAA (0, 2, 5, 10, 15, 25ppm) were spiked with 
25ppm DAB as an internal standard.  Methyltyrosine was no longer used as an internal 
standard once MALDI-TOF/TOF-MS/MS was used, due to issues with ionizing two 
different parent ions at the same time.  Structural isomer, DAB, has the same molecular 
mass as BMAA, however, has different fragment ions.  It was therefore decided that if 
samples were spiked with the same concentration of DAB regardless of prior presence of 
DAB in a sample, it could be used as an internal standard.  These analyses were run in 
triplicate for validation procedures.  Figure 28 represents the spectra for one replicate of 
each concentration.  As the concentration of BMAA increases, the intensity of the signal 
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at 102 m/z increases.  The intensity of the signal of DAB, remains constant.  Following 
current literature, these fragment ions are specific to each analyte.  Figure 29 represents 
the representative calibration curve for the average ratio of peak intensities of BMAA and 
DAB (IS).  The error bars were calculated using the standard deviation.  In this linear 
regression, a R2 value of 0.9983 is seen, showing good linearity with DAB as an internal 
standard.  The same parameters were used for each spectra, allowing for consistency and 
reproducibility.   
 
Figure 28. Positive Ion MALDI-TOF/TOF-MS/MS spectrum of BMAA and DAB (IS) with 
CHCA as the matrix.  BMAA Concentrations ranged from 0-25ppm and the concentration of 
DAB was at 25ppm.  The BMAA fragment ion is seen at 102 m/z and the DAB fragment ion at 
101 m/z.  
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Figure 29. Representative calibration curve for the concentrations of BMAA in ppm against the 
peak intensity ratios of BMAA to DAB (IS) with CHCA as the MALDI matrix.  Parent ions for 
BMAA and DAB are 119 and their respective fragments are 102 and 101.  Concentrations of 
BMAA ranged from (0-25ppm) and the concentration of DAB was 25ppm.  Error bars were 
calculated using the standard deviation. 
 
4.3.2. ANALYSIS OF 13C-BMAA 
Within this set of experiments, the use of 13C-BMAA as an internal standard was 
explored.  As described in chapter 2, 13C-BMAA was synthesized in our laboratory at 
Florida International University.  In current literature, deuterated BMAA is often used as 
an internal standard.  The use of 13C-BMAA as an internal standard could have multiple 
benefits: visualization with NMR, more stability than deuterated BMAA, and similar 
fractionation to BMAA.  In this set of experiments, 13C-BMAA solution was spotted 
directly on top of air-dried CHCA matrix and compared to the spectra of a mixture of 
300μM BMAA with 100μM DAB.  Spectra of the fragment ions of BMAA, DAB, 
and 13C-BMAA for the transitions 119>102, 119>101, and 120>103, respectively, can be 
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seen in Figure 30.  Note that each analyte shows fragmentation peaks that differ by 1 m/z 
for this transition.  The transitions 119>73 and 119>43.8 for BMAA and 120>74 and 
120>44.7 are seen in the spectra of Figure 31.   
The percent yield of 13C labelled BMAA was questioned with the LC-MS/MS 
data, and was therefore not used as an internal standard for the remainder of the 
experiments.   
 
Figure 30. Positive Ion MALDI-TOF/TOF-MS/MS spectrum of BMAA and DAB (top), and 13C-
BMAA (bottom) with CHCA as the matrix.  BMAA Concentration was at 300μM, the 
concentration of DAB was 100μM, and the concentration of 13C-BMAA was at 300μM.  The 
BMAA fragment ion is seen at 102 m/z, DAB at 101 m/z, and 13C-BMAA at 103 m/z. 
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Figure 31. Positive Ion MALDI-TOF/TOF-MS/MS spectrum of BMAA (top) and 13C-BMAA 
(bottom) with CHCA as the matrix.  BMAA Concentration was at 300μM and the concentration 
of 13C-BMAA was at 300μM.  The BMAA fragment ions are seen at 73 m/z and 43.8 m/z, 
and 13C-BMAA at 74 m/z and 44.7 m/z. 
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Bovine serum albumin was hydrolyzed overnight as described in the methodology 
section.  The hydrolyzed solution was separated into five samples and spiked with 50ppm 
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amount of noise.  The peak shape and resolution rapidly decrease below the BMAA 
concentration of 125ppm.     
 
 
Figure 32. Positive Ion MALDI-TOF/TOF-MS/MS spectrum of BMAA and DAB (IS) in a 
hydrolyzed BSA solution with CHCA as the matrix.  BMAA concentrations ranged from 0-
125ppm, and the concentration of DAB in each spectra was 50ppm.  The fragment ions are seen 
at 102 m/z for BMAA and 101 m/z for DAB.  Note that below 125ppm, the peak for BMAA at 
102 m/z is split into two peaks at 102 m/z and 103 m/z and the signal intensity is greatly reduced. 
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4.3.4. BMAA ANALYSIS IN BIOLOGICAL TISSUES 
Hydrolyzed biological tissue solution was separated into five samples and spiked 
with 50ppm DAB (IS) and increasing amounts of BMAA (10, 25, 50, 75, and 100ppm).  
Two spots of each concentration were deposited onto the MALDI plate.  MALDI-
TOF/TOF-MS/MS analysis was performed on the sample with the highest concentration 
of BMAA (100ppm).  Ionization of the analyte was not possible.  The data and spectra 
are not included in my thesis, because of the inability to qualify or quantify the analyte of 
interest (BMAA) or the internal standard (DAB).  
As a result of the inability to ionize the analyte of interest (BMAA) and the 
internal standard (DAB), additional biological samples (shrimp) were prepared using a 
solid-phase extraction clean-up method that was described in chapter 2.  Post SPE clean-
up, five samples, comprised of hydrolyzed tissue, spiked with 25ppm DAB (IS) and 
increasing concentrations of BMAA (0, 1, 10, 75, and 200ppm) were spotted onto the 
MALDI plate.  Two spots of each concentration were deposited, using the dried droplet 
method.  MALDI-TOF/TOF-MS/MS analysis was performed for each concentration in 
triplicate.   
Figure 33 represents the spectra for one replicate of each concentration.  As the 
concentration of BMAA increases, the intensity of the signal at 102 m/z increases.  The 
intensity of the signal of DAB, remains constant.  Based on current literature, these 
fragment ions are specific to each analyte.  Figure 34 represents the representative 
calibration curve for the average ratio of peak intensities of BMAA and DAB (IS).  The 
error bars were calculated using the standard deviation.  In this linear regression, a R2 
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value of 0.9999 is seen, showing good linearity with DAB as an internal standard.  The 
same parameters were used for each spectra, allowing for consistency and 
reproducibility.  The method of standard addition was used to calculate the concentration 
of BMAA in the unspiked sample.  Based on the linear regression, the unspiked sample 
contains ~234ppm BMAA.  To relate this back to the original sample, in 1g of biological 
tissue (shrimp) collected from the Florida Bay, there is approximately 234µg/g of 
BMAA.  This value falls within the reported ranges of other studies seen in table 1.   
 
Figure 33. Positive Ion MALDI-TOF/TOF-MS/MS spectrum of BMAA and DAB (IS) in a 
hydrolyzed biological tissue (shrimp) with CHCA as the matrix.  Spiked BMAA concentrations 
ranged from 0-200ppm, and the concentration of DAB in each spectra was 25ppm.  The fragment 
ions are seen at 102 m/z for BMAA and 101 m/z for DAB.   
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Figure 34. Representative standard addition calibration curve for the concentrations of BMAA in 
ppm against the peak intensity ratios of BMAA to DAB (IS) with CHCA as the MALDI matrix.  
Parent ions for BMAA and DAB are 119 and their respective fragments are 102 and 101.  Spiked 
concentrations of BMAA ranged from (0-200ppm) and the concentration of DAB was 25ppm.  
Error bars were calculated using the standard deviation.  The calculated concentration of BMAA 
in the unspiked sample is 234.52ppm. 
 
4.4. VALIDATION PROCEDURES 
As a result of complications with matrix effects that resulted in increased limits of 
detection, validation procedures of the MALDI-TOF/TOF-MS/MS method was 
performed using BMAA and DAB (IS) standards in an aqueous solution.  The following 
validation procedures show proof of concept and proof of method.  Varying 
concentrations of BMAA (0, 2, 5, 15, and 25ppm) were spiked with 25ppm of DAB as an 
internal standard.  Each concentration was spotted in triplicate, analyzed, and the data 
was exported to Microsoft Excel for processing.  Method validation followed protocols 
published by the International Conference on Harmonisation of Technical Requirements 
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for Registration of Pharmaceuticals for Human Use, entitled Validation of Analytical 
Procedures: Text and Methodology Q2(R1).             
4.4.1. LIMIT OF DETECTION 
The determination of the limit of detection was derived from the standard 
deviation of the blank.  Five replicates of a blank, air-dried CHCA matrix, were analyzed 
using the optimized MALDI-TOF/TOF-MS/MS method with the same parameters as the 
other samples.  The peak intensities of the analytical background at 102 m/z was exported 
to Microsoft Excel (Table 4).  These values were used to calculate the mean and the 
standard deviation.  The standard deviation, in accordance to the analytical background 
response of the blank and the mean were used to calculate the limit of detection using the 
equation (Figure 35), where σ is the standard deviation, and m is the mean of the peak 
intensities of the five blanks at 102 m/z.   
𝐿𝐿𝐿𝐿𝐿𝐿 = 3 �𝜎𝜎
𝑚𝑚
� 
 
Table 4. Peak intensities analytical background response at 102 m/z. 
BLANK 
SAMPLE 
# 
PEAK 
INTENSITY 
AT 102 m/z 
PEAK 
INTENSITY 
AT 101 m/z 
Ratio 
BMAA/DAB 
MEAN STD 
DEV 
LOD 
(ppm) 
LOQ 
(ppm) 
BLANK 1 4.236 31.682 0.134 0.149 0.081 10.318 34.393 
BLANK 2 4.139 34.250 0.121     
BLANK 3 1.400 21.583 0.065     
BLANK 4 4.847 17.019 0.285     
BLANK 5 2.084 14.559 0.143     
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Figure 35. Representative calibration curve for the concentrations of BMAA in ppm against the 
peak intensity ratios of BMAA to DAB (IS) with CHCA as the MALDI matrix.  Parent ions for 
BMAA and DAB are 119 and their respective fragments are 102 and 101.  Concentrations of 
BMAA ranged from (0-25ppm) and the concentration of DAB was 25ppm.  Error bars were 
calculated using the standard deviation.  Limit of detection and limit of quantitation were 
calculated by the measurement of the ratios of peak intensities of fragment ion 102 m/z over 101 
m/z in the background response of the blank (5 replicates).   
 
4.4.2. LIMIT OF QUANTITATION 
The determination of the limit of quantitation was also based on the mean and standard 
deviation of the blank. The following equation was used to calculate the limit of detection:  
𝐿𝐿𝐿𝐿𝐿𝐿 = 10 �𝜎𝜎
𝑚𝑚
� 
The value for the limit of quantitation is shown in figure 35.   
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4.4.3. ACCURACY 
Accuracy was determined using the linear regression.  Three concentration values 
were chosen (high, medium, and low) and were analyzed in triplicate.  The calculated 
experimental concentration was found using the equation for the linear regression line 
(Figure 35).  The mean was then calculated for each concentration and the percent 
recovery was calculated using the equation.  
% 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 = �𝐴𝐴𝑅𝑅𝑅𝑅𝑅𝑅𝐴𝐴𝐴𝐴𝑅𝑅 𝐶𝐶𝑓𝑓𝐶𝐶𝐶𝐶𝑠𝑠𝐶𝐶𝑓𝑓𝐶𝐶𝐶𝐶 − 𝐴𝐴𝑅𝑅𝑅𝑅𝑅𝑅𝐴𝐴𝐴𝐴𝑅𝑅𝐶𝐶𝑏𝑏𝐶𝐶𝐶𝐶𝑏𝑏𝑏𝑏
𝐶𝐶𝐶𝐶ℎ𝐶𝐶𝑓𝑓𝑓𝑓𝐶𝐶𝐶𝐶𝑠𝑠𝐶𝐶𝐶𝐶𝐶𝐶
� 𝑥𝑥 100 
 The calculated concentrations for each replicate and their respective means can be 
seen in Table 5.  The percent recovery values for BMAA using MALDI-TOF/TOF-
MS/MS are 75.2 - 99.21%.    
Table 5.  Calculated values for percent recovery. 
Concentration 
(ppm) 
Calculated 
Concentration 
#1 (ppm) 
Calculated 
Concentration #2 
(ppm) 
Calculated 
Concentration 
#3 (ppm) 
MEAN 
(ppm) 
LOW (2ppm) 2.36 2.65 0.89 1.96 
MEDIUM 
(15ppm) 
15.23 12.76 15.88 14.62 
HIGH (25ppm) 21.27 30.79 23.73 25.26 
 
4.4.4. PRECISION 
The precision of the MALDI-TOF/TOF-MS/MS method was calculated using the 
standard deviation of the above mentioned series of concentrations.  The same 
concentrations and replicates were used for the calculation of percent of relative standard 
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deviation.  The standard deviation of each concentration was calculated as well as the 
mean.  The percent of relative standard deviation was calculated using the equation. 
%𝑅𝑅𝑅𝑅𝐿𝐿 =  �𝜎𝜎
?̅?𝑥
� 𝑥𝑥100 
The percent relative standard deviation values for BMAA with MALDI-
TOF/TOF-MS/MS are 11.26-48.14%.   
4.4.5. RANGE AND LINEARITY  
The linear range of the calibration is from 2ppm to 25ppm as seen in Figure 35.  
Linearity was shown to have a coefficient of determination of 0.9983 (Figure 35).  Non-
linearity was observed when concentrations went below 0.25ppm, which results in a 
decrease of the R2 value.   
4.5. CONCLUSIONS 
The MALDI-TOF/TOF-MS/MS method proved to be a viable alternative to the 
traditional methods such as LC-MS/MS and HPLC of BMAA quantitation and 
separation.  As shown with standards, an amino acid matrix, and a biological tissue 
matrix with SPE clean-up, this method is possible.  With standards, detection was 
possible down to 0.2ppm and validation methods showed an acceptable percent recovery 
range of 75.2-99.21% that would have been increased if a concentration higher than 
2ppm would have been used for the lowest concentration.  The percent relative standard 
deviation again was outside of the acceptable range due to the concentration of the lower 
limit.  If this concentration would have been increased, the percent relative standard 
deviation would have been better.   
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The use of methyltyrosine as an internal standard was successful in full scan, 
however, in TOF/TOF-MS/MS, instrumental limitations did not enable both parent ions 
(BMAA and methyltyrosine) to be ionized at the same time.  As seen in the LC-MS/MS 
data, 13C-BMAA was not successful as an internal standard for MALDI for the same 
reasons it failed for LC-MS/MS, it proved to not be isotopically pure and/or completely 
labeled, resulting in an overestimate of BMAA in a sample.  The use of DAB as an 
internal standard, however, proved to be a viable option.  Since both BMAA and DAB 
share the same parent ion of 118.14, the MALDI laser was able to ionize both amino 
acids at the same time.  As shown in previous literature, common fragment ions of 
BMAA and DAB are 102 m/z and 101 m/z, respectively.  The data produced using 
MALDI-TOF/TOF-MS/MS also shows these fragment ions, and with these fragments, 
successful quantitation of BMAA is possible using MALDI-TOF/TOF-MS/MS.  The 
discrimination capabilities of this method were shown as the method was able to 
discriminate between two structural isomers whose fragmentation ions differ by only       
1 m/z. 
Literature reports levels of BMAA in different matrices to be between 4-350μg/g, 
or approximately 4-350ppm (Table 1).  With these reported values, the use of MALDI-
TOF/TOF-MS/MS would be a viable option to analyze and quantify BMAA in a variety 
of samples.  In sections 4.3.3 and 4.3.4, the MALDI-TOF/TOF-MS/MS method was 
unable to ionize the analyte in these matrices, until an SPE clean-up method was used.  
This proved that sample preparation, including the method of hydrolysis, needed to be 
optimized in order to analyze BMAA in a more complex matrix.  With the BSA matrix, 
the limit of detection for BMAA diminished below 125ppm, and with the biological 
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tissue matrix, no BMAA was detected without an SPE clean-up.  After additional clean-
up steps, the MALDI-TOF/TOF-MS/MS method was capable of ionizing both BMAA 
and DAB in a complex biological matrix.  Additionally, the amount of BMAA in the 
biological sample was calculated with a high level of confidence, based on the R2 value 
of 0.9999 from the linear regression in figure 34.                
5.   DISCUSSION 
Currently on any given day, there are 30,000 cases of ALS, 5.4 million cases of 
Alzheimer’s, and 500,000 Parkinson’s patients in the United States alone, and it is 
thought that out of all of these cases, only 10% are inherited (National Institute of 
Neurological Disorders and Stroke, 2014).  The role of BMAA in neurodegenerative 
diseases is still unknown, however, the consumption of water or food sources that contain 
this amino acid could account for part of the 90% of unknown causes of these diseases.  
With that being said, the development of an analytical platform that is capable of 
analyzing and quantifying BMAA in a variety of matrices is essential to understand the 
extent of human exposure and toxicity.  As the prevalence of neurodegenerative diseases 
increases, so does the interest for the study of what might cause these debilitating 
diseases.   
This study has shown the usefulness and potential of MALDI-TOF/TOF-MS/MS for 
the analysis of BMAA and its structural isomer DAB.  This method has proven to be a 
rapid analysis technique with minimal data processing.  In this study, MALDI-TOF/TOF-
MS/MS instrument parameters were optimized for the analysis of BMAA with a sample 
analysis time of seconds.  However, there are limitations of MALDI-TOF/TOF-MS/MS 
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in the analysis of small molecules.  With increasing complexity of matrices, instrument 
noise made it difficult and in some cases (biological tissue samples), impossible to detect 
the analyte of interest (BMAA) without additional clean-up steps.  The possibility of 
MALDI-TOF/TOF-MS/MS to separate and resolve mixtures that contain structural 
isomers of BMAA with high accuracy and precision is there, however, it is important to 
state that additional research is essential for the use of this method as an analytical tool 
for the analysis of BMAA and other small molecules.       
In terms of LC-MS/MS, although this method is much more sensitive, literature 
reports concentrations of BMAA in complex matrices between 0-2,286μg/g, this sensitive 
of a method could be somewhat unnecessary.  Although LC-MS/MS has a much longer 
analysis time, 10-45 minutes per sample, this method has provided significant data in the 
study of BMAA.  The developed MALDI-TOF/TOF-MS/MS method was able to detect 
BMAA down to 0.2ppm.  In a complex matrix, this limit of detection would obviously 
increase, however, with the concentrations of BMAA reported in current literature, 
anything below 10ppm could be useful for the study of BMAA in biological samples.     
With further research, MALDI-TOF/TOF-MS/MS could compete with traditional 
instrumentation such as LC-MS/MS.  This study shows a proof of concept that a 
MALDI-TOF/TOF-MS/MS method is possible and application to a real world biological 
tissue sample.  To combine MALDI-TOF/TOF-MS/MS with MALDI imaging would 
result in an analytical platform that would allow for minimal sample preparation, rapid 
analysis, and visualization of an analyte in a tissue sample, while also eliminating the 
need for derivatization, chromatographic separation, and modification of amino acids.  
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All of these attributes cannot be obtained with other instrumentation currently used.  All 
of these qualities would greatly benefit the study of BMAA in neurodegenerative diseases 
and further the current understanding of the mechanism by which BMAA acts, its ability 
to biomagnify through the food web, and its role in neurodegenerative diseases.    
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